Haleon (LON:HLN) Announces Earnings Results

Haleon (LON:HLN) issued its quarterly earnings results on Thursday. The company reported GBX 18.60 earnings per share for the quarter, Digital Look Earnings reports. Haleon had a return on equity of 6.54% and a net margin of 9.66%.

Haleon Stock Up 2.9%

Shares of Haleon stock traded up GBX 11.46 during trading hours on Friday, reaching GBX 405.66. The company’s stock had a trading volume of 64,414,406 shares, compared to its average volume of 40,337,660. The company has a market capitalization of £36.13 billion, a P/E ratio of 24.29, a P/E/G ratio of 1.49 and a beta of 0.19. The stock’s fifty day simple moving average is GBX 383.21 and its two-hundred day simple moving average is GBX 365.33. Haleon has a one year low of GBX 325.10 and a one year high of GBX 419.50. The company has a debt-to-equity ratio of 53.36, a quick ratio of 0.93 and a current ratio of 0.84.

Analysts Set New Price Targets

Several brokerages have issued reports on HLN. Deutsche Bank Aktiengesellschaft dropped their price target on Haleon from GBX 340 to GBX 335 and set a “buy” rating on the stock in a research note on Thursday, January 22nd. Jefferies Financial Group reiterated a “buy” rating and set a GBX 450 target price on shares of Haleon in a research report on Wednesday, January 21st. JPMorgan Chase & Co. raised their price target on shares of Haleon from GBX 315 to GBX 335 and gave the stock an “underweight” rating in a report on Wednesday, November 26th. Berenberg Bank lifted their price target on shares of Haleon from GBX 507 to GBX 517 and gave the company a “buy” rating in a research note on Wednesday, November 5th. Finally, Royal Bank Of Canada reissued a “sector perform” rating and set a GBX 370 price objective on shares of Haleon in a research report on Friday, October 31st. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of GBX 407.83.

Haleon Company Profile

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.